NeuroBo Pharmaceuticals Inc. (NRBO): Price and Financial Metrics
NRBO Price/Volume Stats
| Current price | $3.14 | 52-week high | $6.75 |
| Prev. close | $3.06 | 52-week low | $2.89 |
| Day low | $3.00 | Volume | 17,307 |
| Day high | $3.14 | Avg. volume | 1,039,675 |
| 50-day MA | $4.44 | Dividend yield | N/A |
| 200-day MA | $4.00 | Market Cap | 15.40M |
NRBO Stock Price Chart Interactive Chart >
NeuroBo Pharmaceuticals Inc. (NRBO) Company Bio
NeuroBo Pharmaceuticals Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals conducts business in the United States.
Latest NRBO News From Around the Web
Below are the latest news stories about NEUROBO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate NRBO as an investment opportunity.
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityNeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). The IND application supports a Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) for the treatment of obesity |
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced a 1-for-8 reverse stock split of the Company's Common Stock, par value $0.001. Beginning on December 21, 2023, the Company's Common Stock will trade on The Nasdaq Capital Market on a split adjusted basis. |
Life Science Investor Forum: Presentations Now Available for Online ViewingCompany Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Investor Forum sponsored by Zacks Small-Cap Research. held December 14th are now available for online viewing. REGISTER NOW AT: https://bit.ly/41oBqxg The company presentations will be available 24/7 for 90 days. Investors, adv |
Life Science Investor Forum Agenda Announced for December 14th, 2023NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held December 14th. This event is sponsored by Zacks Small-Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/3tcvQkSIt is recommended that investors pre-register and run the online system check to expedite participat |
NeuroBo to Participate in Investor Conferences in DecemberNeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, Marshall H. Woodworth, Acting Chief Financial Officer and Robert Homolka, Senior Vice President of Clinical Operations, will present a company overview, including updates on the company's promising cardiometabolic assets, DA-1241, in development as a treatment for NASH and DA-172 |
NRBO Price Returns
| 1-mo | -27.65% |
| 3-mo | 2.28% |
| 6-mo | -8.40% |
| 1-year | -41.89% |
| 3-year | -99.64% |
| 5-year | -99.96% |
| YTD | -15.06% |
| 2023 | -35.60% |
| 2022 | -98.04% |
| 2021 | -76.76% |
| 2020 | -40.00% |
| 2019 | -56.79% |
Loading social stream, please wait...